{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:45:09Z","timestamp":1777621509017,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["MRSG-11-149-01-LIB"],"award-info":[{"award-number":["MRSG-11-149-01-LIB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.bbmt.2015.03.014","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T17:21:33Z","timestamp":1429118493000},"page":"1074-1082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results"],"prefix":"10.1016","volume":"21","author":[{"given":"Joseph","family":"Pidala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian C.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo F.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmita","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonel","family":"Ochoa-Bayona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcie","family":"Riches","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.03.014_bib1","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry","volume":"341","author":"Socie","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.03.014_bib5","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","article-title":"Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study","volume":"108","author":"Fraser","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib6","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","article-title":"Duration of immunosuppressive treatment for chronic graft-versus-host disease","volume":"104","author":"Stewart","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2008-10-182592","article-title":"Quality of life after allogeneic hematopoietic cell transplantation","volume":"114","author":"Pidala","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib8","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/asheducation-2008.1.134","article-title":"Recognizing and managing chronic graft-versus-host disease","author":"Lee","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2015.03.014_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V100.1.48","article-title":"Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone","volume":"100","author":"Koc","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood.V72.2.546.546","article-title":"Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation","volume":"72","author":"Sullivan","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib13","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2011.05.016","article-title":"Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study","volume":"18","author":"Gilman","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib15","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib16","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","article-title":"High levels of B-cell activating factor in patients with active chronic graft-versus-host disease","volume":"13","author":"Sarantopoulos","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2015.03.014_bib17","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2004-09-3660","article-title":"Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission","volume":"105","author":"Miklos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2003-03-0984","article-title":"Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors","volume":"103","author":"Miklos","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2007-01-071043","article-title":"Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease","volume":"110","author":"Svegliati","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib20","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2013-08-520072","article-title":"Plasma CXCL9 elevations correlate with chronic GVHD diagnosis","volume":"123","author":"Kitko","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib21","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2007-08-106286","article-title":"Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group","volume":"111","author":"Fujii","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib22","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","article-title":"Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease","volume":"113","author":"Sarantopoulos","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib23","first-page":"86","article-title":"Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease","volume":"90","author":"Abrahamsen","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.03.014_bib24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2008.11.024","article-title":"Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells","volume":"15","author":"D'Orsogna","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","article-title":"Elevated numbers of immature\/transitional CD21\u2212 B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease","volume":"14","author":"Greinix","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib26","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2010-07-295766","article-title":"Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia","volume":"117","author":"Kuzmina","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib27","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2014-04-571125","article-title":"Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD","volume":"124","author":"Khoder","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib28","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2010-10-307819","article-title":"Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease","volume":"117","author":"Sarantopoulos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib30","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib31","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","article-title":"Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence","volume":"119","author":"Arai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4049\/jimmunol.181.1.822","article-title":"Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis","volume":"181","author":"Beum","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2015.03.014_bib34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2015.03.014_bib35","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.4049\/jimmunol.1202588","article-title":"Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties","volume":"190","author":"Rafiq","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2015.03.014_bib36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma","volume":"156","author":"Barth","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.03.014_bib37","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMc1308488","article-title":"Ofatumumab for rituximab-resistant nephrotic syndrome","volume":"370","author":"Basu","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.03.014_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4049\/jimmunol.1202645","article-title":"Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy","volume":"190","author":"Bologna","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2015.03.014_bib39","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2010.27.9836","article-title":"Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies","volume":"28","author":"Cheson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.03.014_bib40","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Study I. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2012-12-472027","article-title":"Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma","volume":"122","author":"Matasar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib42","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.clml.2013.02.022","article-title":"Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature","volume":"13","author":"Nader","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2015.03.014_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/ejh.12065","article-title":"A\u00a0case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p","volume":"90","author":"Namberger","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2015.03.014_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bjh.12857","article-title":"Efficacy of ofatumumab against rituximab-resistant B-CLL\/SLL cells with low CD20 protein expression","volume":"166","author":"Shimada","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.03.014_bib45","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.7717\/peerj.31","article-title":"Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells","volume":"1","author":"Small","year":"2013","journal-title":"PeerJ"},{"key":"10.1016\/j.bbmt.2015.03.014_bib46","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib47","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib48","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/art.27524","article-title":"Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I\/II study","volume":"62","author":"Ostergaard","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2015.03.014_bib49","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.03.014_bib50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbmt.2013.03.014","article-title":"Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium","volume":"19","author":"Pidala","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3324\/haematol.2011.055186","article-title":"Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.03.014_bib52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbmt.2013.11.025","article-title":"Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease","volume":"20","author":"Palmer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib53","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/bmt.2013.70","article-title":"Comorbidity burden in patients with chronic GVHD","volume":"48","author":"Wood","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.03.014_bib54","doi-asserted-by":"crossref","unstructured":"Sahaf B, Arai, S, Otani, J, et\u00a0al. Rituximab provides steroid-sparing therapy in new-onset chronic graft-versus-host disease. American Society for Blood and Marrow Transplantation Meeting. Salt Lake City, Utah;\u00a02013.","DOI":"10.1016\/j.bbmt.2012.11.081"},{"key":"10.1016\/j.bbmt.2015.03.014_bib55","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2009.04.003","article-title":"Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"15","author":"Kharfan-Dabaja","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:41Z","timestamp":1761058301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911500186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S108387911500186X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}